Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) Share Price

Company Profile

Business description
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
Contact
No. 666 Xinhua Avenue
Chengdu Cross-Strait Science and Technology Industry Development Park
Wenjiang
Sichuan
Chengdu
CHN
T: +86 4006887002
https://www.kelun-biotech.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,045

Recommended

With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.

Dan Romanoff, CPA | 08 May 2026

Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.

Seth Goldstein, CFA | 08 May 2026

With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.

Jacob Robbins | 08 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,980.50	31.60	-0.35%
CAC 40	8,139.33	62.75	-0.77%
DAX 40	24,444.76	218.85	-0.89%
Dow JONES (US)	49,596.97	313.62	-0.63%
FTSE 100	10,205.06	71.89	-0.70%
HKSE	26,393.71	232.57	-0.87%
NASDAQ	25,806.20	32.75	-0.13%
Nikkei 225	62,713.65	120.19	-0.19%
NZX 50 Index	13,175.13	95.48	-0.72%
S&P 500	7,337.11	28.01	-0.38%
S&P/ASX 200	8,744.40	36.40	-0.41%
SSE Composite Index	4,179.95	0.14	-0.00%